Body Part, Organ, or Organ Component
Fourth Patient Receives Gene-Edited Pig Kidney in Groundbreaking Clinical Trial
xenotransplantation, clinical trial, gene-edited pig kidney, FDA approval, United Therapeutics, eGenesis, end-stage renal disease, organ shortage
Tenpoint Therapeutics Announces Breakthrough Phase 3 Results for Presbyopia Treatment Following Merger with Visus
Tenpoint Therapeutics, Visus merger, Phase 3 trial, presbyopia treatment, BRIMOCHOL PF, vision drug, ophthalmic therapeutics
Sanofi and Alloy Therapeutics Collaborate on CNS Drug Development Using AntiClastic Antisense Platform
Sanofi, Alloy Therapeutics, AntiClastic Antisense Platform, CNS drug development, blood-brain barrier, RNA therapeutics, genetic medicine
Regeneron Acquires UK-Based Eye Drug Developer Oxular
Regeneron, Oxular, eye drug development, retinal therapeutics, acquisition
Sanofi Acquires Exclusive Rights to Develop and Commercialize Cytokinetics’ Aficamten in Greater China
Sanofi, Cytokinetics, Aficamten, Greater China, Hypertrophic Cardiomyopathy (HCM), Cardiac Myosin Inhibitor, Pharmaceutical Deal
FDA Approves Humacyte’s Symvess: A Revolutionary Off-the-Shelf Artery Implant for Vascular Trauma Repair
FDA Approval, Humacyte, Symvess, Vascular Trauma, Off-the-Shelf Artery Implant, Bioengineered Human Tissue, Extremity Vascular Trauma Treatment
Astellas and Sangamo Therapeutics Partner to Enhance Neurological Gene Therapy with STAC-BBB Capsid
Astellas, Sangamo Therapeutics, STAC-BBB capsid, neurological gene therapy, genomic medicines, blood-brain barrier penetration
Aurion Biotech Advances to Phase III Trials with Promising Allogeneic Cell Therapy for Corneal Oedema
Allogeneic cell therapy, Corneal oedema, Corneal endothelial dysfunction, AURN001, Phase III clinical trials, Vision restoration, Biotechnology, Clinical development
FDA Approves Neurocrine’s Crenessity for Rare Congenital Adrenal Hyperplasia
Neurocrine Biosciences, FDA approval, Crenessity, crinecerfont, congenital adrenal hyperplasia (CAH), rare genetic disease, adrenal gland condition.
PureTech’s Deupirfenidone (LYT-100) Demonstrates Superior Efficacy in Slowing Lung Function Decline in Idiopathic Pulmonary Fibrosis (IPF) Phase 2b Trial
PureTech Health, Deupirfenidone (LYT-100), Idiopathic Pulmonary Fibrosis (IPF), Lung Function Decline, Phase 2b Trial, ELEVATE IPF Trial, Pulmonary Fibrosis Treatment